16:34 EDT Catalyst Pharmaceuticals sees FY23 revenue $380M-$390M, consensus $380.21M
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CPRX:
- Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
- CPRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Catalyst Pharmaceuticals CEO McEnany announces intention to retire
- Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
- Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023